GAITHERSBURG, Md.--(BUSINESS WIRE)--GenVec, Inc. (Nasdaq:GNVC) announced today that it has entered into a collaborative research and development agreement (CRADA) with the U.S. Military Malaria Vaccine Program at the Walter Reed Army Institute of Research (WRAIR) and the Naval Medical Research Center (NMRC) for the development and pre-clinical testing of a malaria vaccine candidate against Plasmodium vivax (P. vivax). More than 50 percent of malaria cases in US military personnel are caused by P. vivax, which is debilitating upon primary infection and can cause recurrent illness years after infection occurs. This malaria strain has a significant negative impact on world economic productivity and is a major threat to military preparedness.
